Healthcare

Underlying EBITDA, which excludes earn-out reassessments, litigation and restructuring charges and other one-off items, was $34.2 million, down 27% on FY25's $47.0 million. The company attributed the decline to generalBusinessdisruption arising from the Cosette transaction process and subsequent legal matters, combined with a deliberate …

MBX Biosciences (NASDAQ: MBX) is advancing a clinical differentiation strategy for canvuparatide in hypoparathyroidism that extends beyond the standard efficacy metrics of calcium normalisation, incorporating kidney function improvement as a key distinguishing feature versus currently available treatment options.